購読する
モデル製品
サービス
前臨床薬効評価
コミュ二ティー
huHSC-NKG Mouse
製品のお見積りを依頼する
当社のカタログから製品を選択してご注文ください。当社チームが詳細な情報をご連絡いたします。
huHSC-NKG Mouse
製品名
huHSC-NKG Mouse
製品ID
C001328
系統名
huHSC-NOD.Cg-PrkdcscidIl2rgem1cya/Cya
背景情報
NKG
状況
このマウス系統を論文で使用する場合は、「huHSC-NKG Mouse（カタログ番号C001328）はサイアジェンから購入しました。」と引用してください。
Immunodeficient Mice
Humanized Immune System Models
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
お見積もりについてはこちらまでご連絡ください
Immunodeficient Mice
Humanized Immune System Models
基本情報
検証 Data
関連リソース
基本情報
遺伝子名
遺伝子別名
gc, p64, [g]c, CD132, gamma(c)
NCBI ID
染色体
Chr X
MGI ID
--
さらに
系統詳細
NKG mice (catalog number: C001316) are a kind of severe immunodeficient mice generated by Cyagen through deleting the Il2rg gene from NOD-Scid mice. NKG mice exhibit deficiency of mature T cells, B cells, and functional NK cells, reduced complement activity, and weak phagocytosis of human-derived cells by macrophages, which are well suited for the transplantation of human hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), adult stem cells and tissues, and patient-derived xenograft (PDX).
huHSC-NKG mice are immune system humanized mouse models constructed by transplanting human hematopoietic stem cells (HSC) into NKG mice after sub-lethal dose irradiation. This model has a long lifespan and can successfully reconstitute a variety of immune cells. Furthermore, huHSC-NKG mice typically do not develop graft-versus-host disease (GvHD) and the reconstitution period can be lengthy.
系統作製戦略
Female NKG mice aged 4-5 weeks were selected to inject CD34+ hematopoietic stem cells (HSCs) through the tail vein after irradiation, and the reconstitution period was 12-16 weeks.
適用分野
Research on the immune system and tumor immunity;
Research on hematopoietic development and blood diseases;
Research on infectious diseases such as HIV and AIDS;
Research on tumor transplantation and anti-tumor drug efficacy.
検証 Data
1. NKG mice (Adult) for human CD34+ HSC immune system reconstruction research
（1）Survival curve
The huHSC-NKG adult mice were free of graft-versus-host disease (GvHD) and maintained a high survival rate of over 70% after 150 days post-engraftment.
Figure 1. The survival curve of huHSC-NKG adult mice.
（2）Growth curve
The huHSC-NKG adult mice maintained normal weight gain after the transplantation of huHSC.
Figure 2. The growth curve of huHSC-NKG adult mice.
（3）Proportion of human leukocytes
The percentage of human leukocytes gradually increased, and the average percentage of human CD45+ cells reached more than 60%.
Figure 3. The proportion of human CD45+ cells in peripheral blood of huHSC-NKG adult mice.
（4）Proportions of human T cells and B cells
The reconstruction of the immune system in this model was dominated by B cells in the early stage. The proportion of B cells gradually decreased and the proportion of T cells gradually increased in the later stage. At 12 weeks post-engraftment, the proportion of T cells began to increase, reaching about 40% at week 16. The proportion of B cells was higher at the early stage, reaching 80%, and decreased to 15% at week 24.
Figure 4. Proportions of human T cells and B cells in huHSC-NKG adult mice.
（5）Proportions of human NK cells and monocytes
The proportions of NK cells and monocytes during immune system reconstitution were low. The average proportion of NK cells maintained at about 2% overall and the proportion of monocytes at week 16 was about 2%.
Figure 5. Proportions of human NK cells and monocytes in huHSC-NKG adult mice.
2. NKG mice (Newborn) for human CD34+ HSC immune system reconstruction research
（1）Survival curve
The huHSC-NKG newborn mice were free of graft-versus-host disease (GvHD). The survival rate of huHSC-NKG newborn mice maintained more than 90% before 100 days post engraftment and the survival rate still maintained more than 80% nearly 150 days post engraftment, which was higher than that of the adult model.
Figure 6. The survival curve of huHSC-NKG newborn mice.
（2）Growth curve
The huHSC-NKG newborn mice maintained normal weight gain after the transplantation of huHSC.
Figure 7. The growth curve of huHSC-NKG newborn mice.
（3）Proportion of human leukocytes
The percentage of human leukocytes gradually increased. The average percentage of human CD45+ leukocytes reached more than 40% after 8 weeks post engraftment and subsequently increased and maintained at about 60%.
Figure 8. The proportion of human CD45+ cells in peripheral blood of huHSC-NKG newborn mice.
（4）Proportions of human T cells and B cells
Similar to the adult model, the reconstruction of the immune system in this model was dominated by B cells in the early stage. The proportion of B cells gradually decreased and the proportion of T cells gradually increased in the later stage. At 12 weeks post-engraftment, the proportion of T cells began to increase, reaching about 40% at week 14. The proportion of B cells was higher than 80% at the early stage and decreased continuously, dropping to 40% at week 20.
Figure 9. Proportions of human T cells and B cells in huHSC-NKG newborn mice.
（5）Proportions of human NK cells and monocytes
The proportions of NK cells and monocytes were higher in this newborn model than that in the adult model. The average percentage of NK cells was more than 10% in the early stage and maintained at about 5% in the later stage. The average percentage of monocytes was higher than 5%. Therefore, the newborn model is more suitable for studies related to myeloid cell targets.
Figure 10. Proportions of human NK cells and monocytes in huHSC-NKG newborn mice.
関連リソース
お問い合わせ
ご不明な点やご質問などございましたら、お気軽にお問い合わせください。担当スタッフがサポートさせていただきます。下記のフォームにご記入いただければ、1〜2営業日以内に折り返しご連絡いたします。
Related Product
All Related ProductsPublications
nano today
2025-05-31
Temporal responsive vesicle-INFγ aptamer-PEI/HA system targeted activation of B-CD4T-Tfh-CD8T cells cascade inhibits TNBC progression
続きを読む
Nano Today
2025-05-31
Temporal responsive vesicle-INFγ aptamer-PEI/HA system targeted activation of B-CD4T-Tfh-CD8T cells cascade inhibits TNBC progression
続きを読む
Translational Oncology
2025-01-26
LncRNA TCL6 regulates miR-876–5p/MYL2 axis to suppress breast cancer progression
続きを読む
Translational Oncology
2025-01-27
LncRNA TCL6 regulates miR-876–5p/MYL2 axis to suppress breast cancer progression
続きを読む
Items: 1 to 4 of 4
1
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。